Cargando…
SARS COV-2- IgG antibodies in blood donors in pandemic – A game changer for policy makers
BACKGROUND: A novel beta coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative pathogen for the present pandemic. The objective of the study was to measure the levels of IgG antibodies targeting the SARS-CoV-2 during the peak period of...
Autor principal: | Mahapatra, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Masson SAS on behalf of Société française de transfusion sanguine (SFTS).
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511886/ https://www.ncbi.nlm.nih.gov/pubmed/34653615 http://dx.doi.org/10.1016/j.tracli.2021.10.004 |
Ejemplares similares
-
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
por: Uyoga, Sophie, et al.
Publicado: (2021) -
The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia
por: Mahallawi, Waleed H., et al.
Publicado: (2021) -
IgG antibodies to SARS-CoV-2 in asymptomatic blood donors at two time points in Karachi
por: Hasan, Muhammad, et al.
Publicado: (2022) -
SARS-CoV-2 IgG Surveillance in Asymptomatic Blood Donors and Health Workers
por: Chandra, Tulika, et al.
Publicado: (2021) -
Seroprevalence of SARS-CoV-2 IgG antibody among healthy blood donors: a single centre study
por: Jaiswal, Ram, et al.
Publicado: (2022)